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Abstract 
It is now apparent that antigen-specific T-cells are activated in certain patients with drug-induced liver injury (DILI). Since cross-talk between hepatocytes and immune cells is likely to be critical in determining the outcome of drug exposure, the aim of this study was to profile the signals released by drug-treated hepatocytes and to characterise the impact of these molecules on dendritic cells. Human hepatocytes were exposed to three drugs (flucloxacillin, amoxicillin and isoniazid) associated with DILI potentially mediated by the adaptive immune system as drug-specific T-cells have been isolated from DILI patients, and the metabolite nitroso-sulfamethoxazole (SMX-NO). Hepatocyte toxicity, cytokine release and activation of oxidative stress pathways were measured. Supernatants were transferred to monocyte-derived dendritic cells and cell phenotype and function were assessed. High-mobility group box 1 protein (HMGB1) and lactate dehydrogenase release as well as adenosine triphosphate depletion occurred in a drug-, time- and concentration-dependent manner with SMX-NO and flucloxacillin, whereas isoniazid and amoxicillin were non-toxic. Furthermore, drug-induced activation of Nrf2 marker genes was observed when hepatocytes were exposed to test drugs. The disulphide isoform of HMGB1 stimulated dendritic cell cytokine release and enhanced the priming of naive T cells. Incubation of dendritic cells with supernatant from drug-treated hepatocytes resulted in two distinct cytokine profiles. SMX-NO/flucloxacillin stimulated secretion of TNF-α, IL-6, IL-1α and IL-1-β. Isoniazid which did not induce significant hepatocyte toxicity, compared with SMX-NO and flucloxacillin, stimulated the release of a panel of cytokines including the above and IFN-γ, IL-12, IL-17A, IP-10 and IL-10. Collectively, our study identifies drug-specific signalling pathways between hepatocytes and immune cells that could influence whether drug exposure will result in an immune response and tissue injury.
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Introduction 
Drug-induced liver injury (DILI) with a delayed onset is rare but remains a major challenge to drug development and drug therapy. It is the most documented adverse drug reaction associated with drug attrition, drug regulation and the withdrawal of drugs that have already been approved for clinical use (Andrade et al., 2006; Aubrecht et al., 2013). The incidence of DILI is estimated at approximately 1 in 10,000 to 1 in 100,000, and accounts for about 50% of acute liver failures (Stephens et al., 2012; Ostapowicz et al., 2002; Lee et al., 2011; Fontana et al., 2014). DILI can be broadly classified into type A and type B reactions. Type A reactions are predictable, occurring in a dose-dependent manner, and can be easily replicated in experimental models. In contrast, Type B reactions, the focus of this manuscript, are usually unpredictable and idiosyncratic in nature. Adverse events present with a complex dose-dependency and are difficult to replicate using in vivo models. 

The association between human leucocyte antigen (HLA) alleles and increased susceptibility to certain forms of DILI suggests a role for the adaptive immune system in the pathogenesis. Notable HLA alleles associated with increased DILI risk include: B*57:01 (flucloxacillin) (Daly et al., 2009), DRB1*07:01 (ximelagatran, lapatinib) (Kindmark et al., 2008; Schaid et al., 2014), ticlopidine (A*33:03) (Hirata et al., 2008) and DRB1*15:01 (lumiracoxib, co-amoxiclav) (Singer et al., 2010; Hautekeete et al., 1999). Furthermore, the identification of drug-specific T-cells in DILI patients strengthens the evidence for the involvement of the adaptive immune system. Monshi et al characterized IFN-γ and granzyme-B secreting flucloxacillin-specific T-cells in the blood of patients with flucloxacillin-induced liver injury (Monshi et al., 2013). Also, T-cells isolated from patients with amoxicillin/clavulanic acid and TB medication-induced liver injuries have been shown to proliferate and secreted IFN-γ in response to the drug treatment (Kim et al., 2015; Usui et al., 2016).  

Although HLA alleles predispose individuals to DILI, it is not an absolute requirement for DILI progression (i.e, most patients expressing an HLA risk allele do not develop DILI when exposed to the drug) (Urban et al., 2014). Hence, it is important to investigate the role of HLA alleles in the context of other confounding risk factors. Chemical and oxidative stress signalling from liver cells following drug exposure may be one such factor, because innate immune activation following stress signalling may promote T lymphocyte activation/polarization (Crispe, 2009; Crispe, 2014). For example, hepatocyte high-mobility group box 1 protein (HMGB1) is thought to act as a signalling molecule promoting dendritic cell maturation, whereas nuclear factor (erythroid-derived 2)-like 2 (Nrf2) responds to chemical stress by directing an adaptive transcriptional response through the increased expression of cytoprotective genes including AKR1B10, NQQ1, SRXN1 and TXNRD1.  These signals may be an important contributory factor to DILI as they help to overcome T-cell tolerance in the liver, which is controlled for the large part by antigen presenting cells. Furthermore, DILI drugs might stress hepatocytes and enhance the sensitivity of hepatocytes to the direct cytotoxic actions of cytokines released by the innate and adaptive immune system (Roth et al, 2017). 

Recently, Oda et al (2016) developed a cell-based assay to identify inflammatory genes that might represent predictive biomarkers for DILI. This assay offers an advantage when compared to hepatocyte cell viability assays and the assessment of cellular stress pathways because it provides information on the potential involvement of the innate immune system in DILI. The authors utilised either HepG2 (human liver cancer cell line) or HepaRG (hepatic stem cell line) as hepatocyte-like cells, and HL60 cell line (neutrophil-derived promyelocytic leukemia cell line) to represent immune cells. While this system provides mechanistic information about tissue and immune cell signalling, there are still questions about whether the information gained from experiments with cell lines adequately mirrors the signalling observed with primary cells. Thus, the aim of this study was to utilize primary human hepatocytes and human-monocyte derived dendritic cells to examine the ability of hepatic cells to release, in a drug-specific manner, signalling molecules that influence the activity of innate immune cells. We tested the hypothesis that hepatocyte stress/death results in mediator release that stimulates the dendritic cells transforming them into an activated state that promotes antigen presentation and polarization of the newly primed T-cells into a more effector phenotype. We focused on three concentrations that induced various levels of hepatocyte cell death. To do this, hepatocytes were exposed to graded concentrations of the test compounds and toxicity dose-response curves were generated. A low (non-toxic concentration), medium and a high (toxic concentration) concentration were selected in order to understand how cell death per se impacts on the molecules released from hepatocytes. Although the drug concentrations used exceed the reported Cmax in humans, it is possible that there is significant drug accumulation in the liver of patients with DILI. Furthermore, it is the concentration of reactive intermediate and/or protein adducts, not the parent drug, which determines whether cells of the innate immune system are activated (Martin et al., 2012). For this reason, we focussed on four compounds that all form protein adducts directly in solution with no requirement for additional metabolism to study their effects on hepatocyte/dendritic cell signalling. Importantly, the concentrations selected have been used previously to study the formation of protein adducts in vitro and activate drug hapten-specific T-cells from patients with DILI. The data generated provides drug-specific information on the signalling molecules released from hepatocytes and how hepatocyte-derived signals affect the innate immune system.


Materials and Methods
Test compounds: Amoxicillin, flucloxacillin, isoniazid and nitroso-sulfamethoxazole were selected as model compounds as they are commonly associated with type B DILI. In fact, Urban et al (2012) listed these compounds as the first, second, fifth and sixth most common causes of type B DILI. Furthermore, we have previously isolated T-cells reactive to amoxicillin, flucloxacillin and isoniazid from patients with DILI (Monshi et al., 2013; Kim et al., 2015), whereas nitroso sulfamethoxaozle (SMX-NO) is widely used as a probe to study mechanisms of drug-specific T-cell activation (Ogese et al., 2015; Schnyder et al., 2000; Castrejon et al., 2010). Most importantly, all four compounds form haptens spontaneously in cell culture medium (Callan et al., 2009; Monshi et al., 2013; Meng et al., 2015); thus, metabolic competency is not an absolute requirement for the generation of drug protein adducts. 
The human Cmax for amoxicillin, flucloxacillin, isoniazid and sulfamethoxazole are 0.05 mM (Baglie et al., 2005), 0.03 mM (Jenkins et al., 2009), 0.04 mM (Bhatt et al., 2014) and 0.18 mM (Macingwana et al., 2012), respectively. Although the concentrations of test drugs selected for this study significantly exceed the reported Cmax in humans, similar concentrations have been used in in-vitro assays to study the activation of T-cells from patients with DILI (Castrejon et al., 2010, Monshi et al., 2013, Kim et al., 2015; Usui et al., 2016). Specifically, T-cells from patients with flucloxacillin-, co-amoxiclav- and isoniazid-induced DILI are optimally activated with mM concentrations of the drugs. The level of protein adduct formed in the in vitro assay is the same as that measurable in patient plasma. Thus, the level of hepatocyte/dendritic cell exposure to protein adducts is relevant to the therapeutic situation. It is difficult to relate the Cmax for sulfamethoxaozle to the concentration of SMX-NO used in the study. Approximately 1.5% of an ingested dose of sulfamethoxaozle is converted to a hydroxylamine metabolite (Gill et al., 1996), the pre-cursor of SMX-NO. It should be noted that SMX-NO is unstable in solution. After 1h, less than 1% of the drug metabolite is detectable (Naisbitt et al., 2001; Naisbitt et al., 2002). Thus, it is likely that hepatocytes are exposed to nM or low microM concentrations of SMX-NO for the majority of our in vitro experiments.
    
Isolation of primary human hepatocytes from liver tissue: Liver biopsies were obtained from consented donors following hepatic resections of varying aetiologies conducted at the University of Liverpool teaching hospital, Aintree. All donors provided written informed consent to partake in the study approved by the Liverpool local research ethics committee. Primary human hepatocytes were isolated using a previously published collagenase perfusion technique (Seglen, 1975). Briefly, liver resections were perfused using HEPES buffer (1x) to remove residual blood in the tissue following surgical resection. This was followed by the digestion of tissue matrix with collagenase type IV (Sigma Aldrich, UK) to release hepatocytes. Freshly isolated hepatocytes were cultured in Williams E supplemented by L-glutamine (2 mM), penicillin (100 μg/ml), streptomycin (100 U/ml), insulin-transferin-selenium (100x) and dexamethasone (1 μM/ml) using the desired cell culture plate formats pre-coated with collagen-I (Corning Flintshire, UK). This procedure yields around 90% hepatocytes plus 10% other liver cell types. Hepatocyte viability was determined by trypan blue exclusion of dead cells, and only isolations yielding ≥ 85% were used for functional assays. On the other hand albumin production was used as a functional marker (data not shown). The additional cell types include liver fibroblasts and hepatocyte progenitor cells some of which do not lay down in hepatocyte culture. Hence, the culture contained cells of predominantly hepatocyte identity, which was confirmed using hepatocyte markers. It is possible that the drug-dependent cytokine secretion observed herein may partly derive from the non-hepatocytes; however, further purification is not feasible as this results in a decrease in cell viability and function. 

Generation and culture of monocyte-derived dendritic cells: Peripheral blood mononuclear cells were isolated from venous blood (120 ml) of consented individuals. Using antibody-conjugated magnetic micro beads and columns (Miltenyi Biotec, Bisley, UK) CD14+ monocytes were positively selected for dendritic cells generation using previously published protocol (Faulkner et al., 2012). Differentiation of CD14+ monocytes to dendritic cells was enhanced by the addition of GM-CSF (800 U/ml) and IL-4 (800 U/ml) (PeproTech, London, UK), to culture medium on days 0, 2 and 4. By day 7 monocyte-derived dendritic cells were ready to be used for functional assays and for characterization of dendritic cell surface markers expressed upon stimulation with graded concentrations of test drugs, hepatocyte culture supernatant or 10 g/ml LPS as a positive control.

Determination of cell viability and cytotoxicity using lactate dehydrogenase release and adenosine triphosphate depletion assays: To establish the optimum time point for measurement of cytotoxicity, primary human hepatocytes (105 cells) were plated onto collagen coated plates for an initial 3h to allow hepatocytes to adhere to the plates. Cells were then washed and incubated in fresh culture medium overnight. Subsequently, cells were cultured with flucloxacillin (1-10 mM) at 37°C, 5% CO2 for 0.5, 1, 6 and 24 h using 96 well, flat bottomed collagen-I coated plate. Percentage lactate dehydrogenase (LDH) release and adenosine triphosphate (ATP) depletion were analysed using kit-based assays according to manufacturers’ instructions. The dose-dependent toxicity curves generated in the ATP depletion experiments were used to determine study concentrations for each test drug in the mechanistic studies outlined below. LDH cytotoxicity kit was purchased from Roche Applied Sciences (Mannheim, Germany) and ATP cell viability assay kit was obtained from Promega (Madison, USA).  In subsequent experiments, primary human hepatocytes were cultured with amoxicillin (1-10 mM), flucloxacillin (1-10 mM), isoniazid (2-20 mM) and SMX-NO (25-800 µM) for 24 h before the assessment cytotoxicity. For subsequent experiments, three concentrations of each test drug were selected. The concentrations selected included the maximum non-toxic concentration, a concentration associated with approximately 50% hepatocyte toxicity and a concentration associated with approximately 75% hepatocyte toxicity. With amoxicillin and isoniazid, 50 and 75% hepatocyte toxicity was not detected. Thus, amoxicillin concentrations were selected to match flucloxacillin, while with isoniazid the maximum concentrations were used (i.e., 10 and 20mM)   

To investigate whether the toxic effect of flucloxacillin on primary human hepatocytes was drug-specific, hepatocytes were exposed to the same concentrations of the β-lactam antibiotic piperacillin, (1-10 mM for 24 hours), which is not associated with a high incidence of DILI (Whitaker et al.,2012). Cells were then assessed for cytotoxicity using LDH release and ATP depletion assays. 

RT-PCR analysis of Nrf2 marker genes: Primary human hepatocytes (5×105) were cultured with test drugs for 24 h using a 24 well, flat-bottomed collagen-I coated plate at 37°C, 5% CO2. Total RNA was extracted from drug-treated hepatocytes using RNeasy mini kit and RNase-free DNase kits from Qiagen (Crawley, UK). The concentrations of RNA in samples were determined using a Nano Drop spectrophotometer (Thermo Scientific, Surrey, U.K.). This was followed by RNA transcription to cDNA using the RT2-First Strand kit, and the determination of relative expression of NQO1, AKR1B10, TXNRD1, and SRXN1 genes using an ABI prism 7000 RT-PCR machine (Applied Biosystems, UK). GAPDH gene was used as the endogenous control to normalise the expression of Nrf2 marker genes. 

ELISA and immunoblotting assay for HMGB1 release from primary human hepatocytes: Analysis of HMGB1 release was performed using ELISA and immunoblotting. Immunoblotting detection has a higher sensitivity while ELISA provided us the opportunity to quantify the amount of HMGB1 in cell culture medium. 

Primary human hepatocytes were cultured with graded concentrations of test drugs for 24h. Cell culture supernatant was harvested centrifuged to remove cell debris, and the levels of HMGB1 determined using an HMGB1 ELISA kit (Hamburg, Germany). Briefly, HMGB1 standard (0-80 ng/ml), positive control or cell culture supernatants were plated onto a high affinity, 96 well microtiter plate pre-coated with anti-HMGB1 antibody, and incubated at 37°C for 24h. The incubation solution was discarded and the plate was washed. Subsequently, enzyme conjugate was added to each well and the plate was incubated for 2h at 25°C. Colour solution was added and after 30 minutes, HMGB1 levels were measured on a photometer at a wavelength of 450 nm. The relative concentrations of HMGB1 in test samples were determined using the calibration curve.

For HMGB1 immunoblotting, primary human hepatocytes were incubated with SMX-NO (50-200 µM), flucloxacillin (1-10 mM), isoniazid (2-20 mM) and amoxicillin (1-10 mM) for 24h. Cell culture supernatants were harvested and centrifuged to remove cell debris followed by SDS-PAGE. Proteins were transferred onto nitrocellulose membrane followed by immunoblotting for HMGB1 expression using a rabbit ant​​i-HMGB1 primary antibody from Abcam (Cambridge, UK) and an anti-rabbit IgG HRP-linked secondary antibody (Cell signalling technology, Massachusetts, USA).

ELISpot cytokine assay: Monocyte-derived dendritic cells (105) were cultured with HMGB1 isoforms (A-D; 100 ng/mL) or LPS (10 µg/mL), as a positive control, in a 96 well, flat bottomed ELISpot plate for 24 h at 37oC, 5% CO2. Secretions of IFN-γ, IL-12p70, IL-12p40, IL-10, IL-6 and TNF-α were determined by ELISpot assay kit (Mabtech, Nacka Strand, Sweden) according to manufacturer’s instructions. These cytokines were selected based on data obtained from preliminary Luminex analysis of a panel of 34 cytokines and chemokines present in hepatocyte culture medium ± drug treatment (data not shown).  

Luminex analysis of cytokines in hepatocyte and dendritic cell culture media: Supernatants from either drug-exposed hepatocytes or from dendritic cells cultured with hepatocyte-conditioned medium for 24h were harvested and centrifuged to remove cell debris. The levels of IFN-γ, IL-10, IP-10, MCP-1, IL-8, TNF-α, IL-6, IL-1α, IL-1β, IL-12p40, IL-12p70, IL-17A, G-CSF, IL-4, IL-5, TNF-α, TNF-β, IL-RA, GM-CSF, IL-1α, IFN-α2, VEGF, BCA-1, 6Ckine and IL-23 were analysed using a Milliplex multiplex assay kit (Darmstadt, Germany) on a BioPlex analyser (Bio-Rad, USA).

Characterisation of dendritic cell surface markers: To investigate the effect of drug exposure on dendritic cell activation, monocyte-derived dendritic cells were cultured with two concentrations of each test drug or supernatants from drug-exposed hepatocyte for 24h. The low concentration of test compound was selected to understand the effect of sub-toxic drug concentrations on dendritic cell phenotype while the high drug concentration was intended to examine the effect of drug exposure in the presence of damaged associated molecular patterns on dendritic cell activation. The expressions of CCR1, CCR7, CXCR4, CD80, CD83, CD58, CD40, E-Cadherin, CCR9, CD209, CD274, CD70, CD54, SLAM, CD275, CD86, MHC class II, TIM-1, CD91, CD270 and CD137L were determined using flow cytometry. A total of 10,000 events were acquired using FSC/SSC characteristics.

Isolation and priming of naive T cells: To explore the effect of the disulphide isoform of HMGB1 on the priming of naïve T-cells, we used a recently established dendritic cell, T-cell co-culture system and SMX-NO as a model drug antigen. The assay involves the culture of dendritic cells with naïve T-cells from healthy donors and drug. The primed T-cells are then restimulated with a second batch of dendritic cells and drug and antigen-specific T-cell responses can be measured using a battery of assays. The priming of naïve T-cells is dependent on drug antigen presentation by dendritic cells; however, the dendritic cells are not stimulated to proliferate with the drug (Faulkner et al., 2012; Faulkner et al., 2016). CD14 positive monocytes and naive T cells were isolated from the peripheral blood mononuclear cells obtained from the blood of consented individuals using magnetic bead separation (Faulkner et al., 2012) Using a cocktail of IL-4 and GM-CSF, CD14 positive monocytes were transformed to dendritic cell phenotype over 7 days. On day 6, dendritic cells were matured with LPS and TNF-α or the disulphide isoform of HMGB1 to enhance antigen presentation. Dendritic cells were then co-cultured with naive T cells (1:25) and SMX-NO plus or minus disulphide HMGB1 for 7 days. On day 7, primed T cells were cultured with a fresh batch of dendritic cells in the presence of SMX-NO and drug-specific response determined using thymidine proliferation assay and ELISpot cytokine assay.

Statistical analysis: Experimental data were expressed as the mean ± standard deviation (SD) of the mean for three independent experiments. Statistical analysis was performed using One way analysis of variance (ANOVA) alongside Dunnett’s multiple comparison test to determine statistical significance between test groups. GraphPad Prism© version 5.04 (GraphPad Prism Software Inc, CA, USA) was employed. A p value of ≤ 0.05 was considered to be statistically significant, and denoted using *. Horizontal lines above bar charts group treatments that were statistically significant.


Results 
Measurement of cytotoxicity after exposure of primary human hepatocytes to four test drugs: In initial experiments, primary human hepatocytes were incubated with flucloxacillin (1-10 mM) for 24 h, and the release of LDH or ATP depletion was determined using plate based assays. At this time-point, flucloxacillin caused a concentration dependent increase in LDH release and ATP depletion. To determine whether hepatocyte toxicity could be detected at earlier time-points, LDH release and ATP depletion were also measured after 0.5, 1 and 6h. Significant change in cell viability was observed only at 24 h hence, for subsequent experiments, primary human hepatocytes were exposed to the test drugs for 24h. SMX-NO and flucloxacillin showed a concentration-dependent ATP depletion (figure 1A). A similar trend was also observed for LDH release when primary human hepatocytes were exposed to test drugs. Amoxicillin and isoniazid were non-toxic at low concentrations; however,  low levels of cell death was observed with 8 mM and 10 mM respectively. At the maximum concentrations investigated, ATP depletion and LDH release did not exceed 40% (figure 1A). 

Similar experiments were conducted with piperacillin, a β-lactam antibiotic not associated with a high incidence of DILI. Piperacillin did not stimulate LDH release or ATP depletion from primary human hepatocytes (figure 1B). 

We next investigated the release of the damage associated molecular pattern, HMGB1 after hepatocytes were exposed to test drugs for 24 hours using ELISA and immunoblotting. Consistent with the cytotoxicity data discussed above, SMX-NO and flucloxacillin caused a significant concentration-dependent release of HMGB1 from primary human hepatocytes (figure 2A and B). The highest concentrations of HMGB1 released were 23.7 ng/ml and 21.8 ng/ml after SMX-NO and flucloxacillin exposure, respectively. A marginal increase in the release of HMGB1 was observed at the highest tested concentrations of amoxicillin and isoniazid, but this was not statistically significant (figure 2C and D). Western blot analysis of HMGB1 in the cell culture media corroborated these findings. 

Drug- and concentration-dependent activation of Nrf2 marker genes: A significant increase in expression of ARK1B10, NQO1, SRXN1 and TXNRD1 was seen with all four drugs (supplementary figure 1). However, greatest increase in expression of all 4 genes was observed with the highest concentration of SMX-NO, which was associated with hepatocyte toxicity. Similarly, toxic concentrations of flucloxacillin (4 and 10 mM) stimulated strong upregulation of two genes (AKR1B10 and SRXN1). In contrast, the gene upregulation induced by amoxicillin and isoniazid was much less marked. 

Redox modifications of cysteine residues in HMGB1 regulate cytokine secretion from dendritic cells: The redox states of the three highly conserved cysteine residues present in the HMGB1 protein are critical for its biological function, chemo-attractive or immune stimulatory activities. To investigate the relationship between HMGB1 release from hepatocytes and immune activation, CD14+ monocyte-derived dendritic cells were cultured with the four different isoforms of HMGB1, A-D and the secretion of six cytokines measured (figure 3A and B). Isoform A, characterised by a disulphide bond between C23 and C45 as well as a thiol residue at C106 induced the secretion of IFN-γ, IL-12p70, IL-12p40, IL-10, TNF-α and IL-6 from dendritic cells. Interestingly, isoform C (fully reduced HMGB1), previously reported as a chemo-attractant and involved in the resolution of inflammation, triggered significant secretion of IL-10 and a low level of IL-12p40 release from dendritic cells. In contrast, the D isoform, with a disulphide bond between C23 and C45, and an oxidised C106 did not induce any significant cytokine secretion; while the B isoform (fully oxidised) induced only low level release of IL-12p40. Lipopolysaccharide (10 µg/ml) was utilised as positive control, and induced significant secretion of all of the cytokines mentioned. Finally, basal levels of TNF-α and IL-6 and were secreted by all dendritic cells but expression was enhanced by exposure to HMGB1 isoform A and LPS stimulation.

Disulfide HMGB1 enhanced the priming of naive T cell to SMX-NO: To investigate whether the activation of dendritic cells by disulfide HMGB1 (isoform A) translated into enhanced antigen presentation, naive T cells were primed to SMX-NO either in the presence of the disulphide isoform of HMGB1 or LPS/TNFα. Addition of disulphide HMGB1 during the 7 day co-culture period significantly enhanced the priming of naive T cells to SMX-NO as demonstrated by an increase in T cell proliferation and interferon-gamma secretion (figure 3C and D). Furthermore, naive T cells primed in the presence of disulphide HMGB1 showed a lower threshold of activation (i.e., T-cells were activated at the lower SMX-NO concentration; p = 0.02) compared with those primed in the absence of disulphide HMGB1 (p = 0.3). 

Dendritic cells exposed to hepatocyte-conditioned medium exhibited two distinct cytokine profiles: The chemical and biological microenvironment can have a profound effect on both the phenotype and function of dendritic cells and on the nature of adaptive immune response that follows antigen presentation to T-cells. Therefore, we were interested in assessing the effect of any signals present in the hepatocyte microenvironment on dendritic cell phenotype and function. Primary human hepatocytes were incubated with the different test drugs for 24 h and the supernatants (referred to as hepatocyte conditioned medium) transferred to monocyte-derived dendritic cells. After 24h, cytokine release was measured by Luminex. Hepatocyte conditioned medium generated by SMX-NO and flucloxacillin treatment stimulated the release of significant quantities of TNF-α, IL-6, IL-1β and IL-1α from dendritic cells (figure 4A). A trend for increased levels of TNF-α release with SMX-NO and flucloxacillin treatment was seen, but this did not reach statistical significance. Importantly, cytokine release was observed with concentrations of drug associated with no toxicity and low levels of hepatocyte toxicity, whereas release was not detected at the highest drug concentration for these 2 drugs, presumably due to extensive direct dendritic cell toxicity.

Hepatocyte conditioned medium generated by isoniazid treatment stimulated dendritic cells to release TNF-α, IL-6, and IL-1α alongside a panel of cytokines including IFN-γ, IL-12, IL-17A, IP-10 and IL-10 (figure 4B). This result was somewhat surprising given that isoniazid did not cause high levels of hepatotoxicity. Much lower levels of cytokine secretion were observed when dendritic cells were treated with amoxicillin hepatocyte conditioned medium. 

Cytokines released directly by hepatocytes were measured to assess their contribution to the results outlined above. Treatment of hepatocytes with SMX-NO, amoxicillin and flucloxacillin was associated with low levels of cytokine secretion, < 200 pg/ml (results not shown). Isoniazid was the only drug to stimulate the release of cytokines above vehicle control levels, namely a 3 fold increase in IL-10.

The hepatocyte conditioned medium still contained the test drugs, which may have had a direct effect on cytokine secretion by the dendritic cells. This was investigated by comparing cytokine release following exposure of dendritic cells to either hepatocyte conditioned medium or test drugs alone for 24h. Interestingly, IP-10, MCP-1 and IL-1RA were selectively upregulated in the presence of hepatocyte conditioned medium generated by SMX-NO (figure 5A). With hepatocyte conditioned medium containing flucloxacillin, an increase in IP-10 and MCP-1 was observed (figure 5B). In contrast, dendritic cells treated with either isoniazid or isoniazid hepatocyte conditioned medium secreted similar levels of cytokines. Data showing secretion of three representative cytokines IL-10, TNF-α and IL-8 are shown in figure 5C. 

Effect of test drugs and hepatocyte conditioned medium on dendritic cell surface phenotype: Dendritic cells were cultured with either test drugs or hepatocyte conditioned medium for 24h and cell surface markers measured by flow cytometry. Several different groups of cell surface markers were analysed: chemotaxis (CCR1, CCR7, CCR9, and CXCR4), activation markers (CD70, TIM-1 and CD137L), maturation markers (CD80, CD86 and MHC II), adhesion molecules (CD54, CD209, and E-cadherin), co-inhibitory receptors (CD270, CD274) and signalling molecules (CD91). Overall, there was little or no significant increase in the expression of the dendritic cell markers when cells were cultured with either test drug or hepatocyte conditioned medium (supplementary tables I-IV). In contrast, LPS/TNF-α treatment increased expression of several chemokine receptors, activation markers, maturation markers, signalling and adhesion molecules. Interestingly, treatment of dendritic cells with SMX-NO-conditioned medium or SMX-NO resulted in a slight increase of CCR1 and CD40 expression (supplementary table IV). However, for treatment with conditioned medium generated by the highest concentration of flucloxacillin and SMX-NO and with drug alone, there were several instances where expression of surface markers on dendritic cells was down-regulated. These markers included CD70, CD83, CD91 and CCR9 for flucloxacillin and CD54, CD58, CD70, CCR9 and CXCR4 for SMX-NO (supplementary tables II and IV).



Discussion
The discovery of (1) strong associations between expression of HLA alleles and susceptibility to DILI and (2) drug-specific T-cells circulating in blood of patients with DILI, show that the adaptive immune system participates in the pathogenesis of certain reactions. Susceptibility to such reactions is a function of the chemistry of the drug, patient genotype and patient phenotype; thus, it is not surprising that tools used during drug discovery fail to predict whether a new chemical entity will cause type B DILI (Roth and Ganey, 2011). Hence, there is an unmet need to develop assays that are comprehensive and representative of the clinical phenotype and pathogenesis of DILI. The aim of this study was to address one aspect of the DILI signalling cascade; drug-specific hepatocyte-derived signals transferred to the immune system. 

DILI presents with a broad spectrum of clinical outcomes but hepatocyte death is the major indicator (Yuan and Kaplowitz, 2013). Dead and dying cells release their intracellular content and an array of molecules act as “danger signals” to promote dendritic cell activation (Tamura et al., 2012; Esser et al., 2012; Wu et al., 2010; Watanabe et al., 2008).  Once a threshold level of danger is exceeded, dendritic cells transform from a tolerogenic to an immunogenic phenotype and (1) secrete polarizing cytokines and (2) activate naïve T-cells by presenting MHC-restricted antigens in the context of co-stimulatory molecules. Furthermore, several groups have reported that the release of cytokines such as IFN- and TNF-α, enhance the direct killing of hepatocytes by DILI drugs (Cosgrove et al., 2009; Herpers et al., 2016; Roth et al., 2017) In this study, primary human hepatocytes and human monocyte-derived dendritic cells were used to better understand some of the important ‘cross-talk’ and molecular signalling between hepatocytes and the innate immune system. Three drugs (amoxicillin, flucloxacillin and isoniazid) and one reactive metabolite (SMX-NO) that modify protein directly or through auto-oxidation were selected as study drugs (Callan et al., 2009; Meng et al., 2015; Ariza et al., 2012; Ariza et al., 2014; Jenkins et al., 2009; Cheng et al., 2008). Thus, the formation of protein adducts in the hepatocyte culture was not dependent on the expression of phase I metabolizing enzymes. In initial experiments, concentration-dependent hepatocyte toxicity was observed with SMX-NO and flucloxacillin. In contrast, amoxicillin and isoniazid were essentially non-toxic. These divergent results allowed us to move forward to explore how hepatocyte signals released in the presence/absence of chemical stress affect dendritic cells.

Extracellular HMGB1, secreted by either activated cells or passively released by injured cells, is a typical damage associated molecular pattern with two major functions namely: nuclear transcription factor and cell signalling in response to inflammation, infection or tissue injury (Lotze et al., 2005; Yang et al., 2010). Disulphide HMGB1 signals through Toll-like receptor 4 (TLR4), myeloid differentiation factor 2 (MD-2) and Receptor for Advanced Glycation End products (RAGE) found on innate immune cells, resulting in dendritic cell activation, accompanied by cytokine secretion and tissue damage (Andersson and Tracey, 2011; Yang et al., 2015; Scaffidi et al., 2002 ). In contrast, fully reduced (thiol) HMGB1 functions as a chemo-attractant molecule by binding to CXCR4 while the fully oxidized (sulphonyl) HMGB1 has no immune function (Andersson and Tracey, 2011). In this study, we found a drug-specific and concentration-dependent release of HMGB1 when primary human hepatocytes were cultured with SMX-NO and flucloxacillin. Furthermore, LC-MS analysis of supernatants from drug-treated hepatocytes revealed 2 distinct HMGB1 peptides (FKDPNAPK and GEHPGLSIGDVAK; data not shown). Multiple attempts to identify the specific HMGB1 isoforms in hepatocyte conditioned medium were unsuccessful. Due to the low concentration of total HMGB1 in the hepatocyte conditioned medium (< 24 ng/ml), dendritic cells were cultured with the four different isoforms of HMGB1 (100ng/ml). Consistent with published data, the A isoform triggered the secretion of all the cytokines profiled: IFN-γ, IL-12p70, IL-12p40, IL-10, TNF-α and IL-6. Surprisingly, the fully oxidised isoform B, thought to be immunologically inert stimulated dendritic cells to secrete low amounts of IL-12p40. Furthermore, isoform C, previously described as devoid of cytokine activity, induced low IL-12p40 and substantial IL-10 secretion. Only isoform D failed to induce cytokine release. IFN-γ, IL-6 and IL-12 would be important in controlling T cell differentiation, possibly favouring Th1 and Th17 subsets (Szabo et al., 2000). Thus, the relative contributions of the different cytokines will dictate whether immune activation occurs and what type of T cell subsets are generated. Moreover, IFN- and TNF-α are critical for enhancing the direct hepatocyte cell death associated with drugs such as diclofenac and trovafloxacin (Roth et al., 2017). Put together, these experiments demonstrate an important role for HMGB1 in controlling dendritic cell function, and suggest this protein may be a critical link between hepatocyte damage and immune activation. To investigate this, the T-cell stimulatory capacity of dendritic cells matured with the disulphide isoform (isoform A) and LPS were compared using an in vitro T-cell priming assay and SMX-NO as a model antigen. Dendritic cells matured with HMGB1 enhanced the priming of naïve T-cells. Following restimulation the primed T-cells proliferated more vigorously and secreted higher levels of IFN-.    

Under normal homeostasis, Nrf2 remains in the cytoplasm by interacting with Kelch like-ECH-associated protein 1 (KEAP1) and Cullin 3, which targets Nrf2 for proteasomal degradation through the ubiquitination pathway (Itoh et al., 1999). In the presence of chemical stress, Nrf2 translocates to the nucleus and binds to the promoter region of antioxidant response element of numerous antioxidative genes responsible for cytoprotection (Itoh et al., 1997). Thus, Nrf2 upregulates the expression of numerous detoxification enzymes, antioxidant/stress response proteins and a number of drug transporters that protect eukaryotic cells against a range of chemical insults (Copple et al., 2012). We investigated the effect of drug exposure on four Nrf2 marker genes (NQO1, AKR1B10, SRXN1 and TNXRD1). Interestingly, the induction of Nrf2 marker genes by SMX-NO and flucloxacillin was directly proportional to the release of LDH and ATP depletion. However, induction of Nrf2 marker genes by isoniazid and amoxicillin was much lower. This data suggests a positive correlation between the cytotoxicity of the drugs examined and their ability to activate the oxidative stress signalling pathway. Furthermore, the data indicates that the cells are attempting to adapt to drug perturbation by launching a defensive strategy prior to cell death.
 
Primary human hepatocytes exposed to test drugs released low levels of pro-inflammatory cytokines and the anti-inflammatory cytokine, IL-10. Monocyte-derived dendritic cells stimulated by hepatocyte conditioned medium released significantly higher levels of cytokines. Two distinct cytokine profiles were observed; a general stress profile with flucloxacillin and SMX-NO treatment (TNF-α, IL-6, IL-1α and IL-1β), and an isoniazid-specific profile (IFN-γ, IL-12p40, IL-12p70, IL-17RA, IP-10 and IL-10). Notably, the highest concentrations of SMX-NO and flucloxacillin, which triggered high levels of toxicity and activation of Nrf2-dependent genes, were not associated with cytokine release. This might have been because dendritic cells were killed with the residual drug. Alternatively, as has been recently reported (Kobayashi et al., 2016), Nrf2 might directly repress the release of TNF-α, IL-6 and IL-1. The pro-inflammatory cytokines TNF-α, IL-6 and IL-1β are known to activate dendritic cells whereas the cytokines of the isoniazid-specific profile are likely to be more important in controlling T-cell polarization. Hepatocyte conditioned medium containing amoxicillin did not stimulate dendritic cell cytokine release, which may have been anticipated as amoxicillin is only associated with a high incidence of DILI when administered in combination with clavulanic acid (Garcia Rodriguez et al.,1996; Salvo et al., 2007; Larrey et al., 1992). Thus, in ongoing experiments we are subjecting clavulanic acid to the same series of analyses. Subsequent experiments with hepatocyte conditioned medium and drug alone revealed that flucloxacillin- and SMX-NO-conditioned medium and the test drugs differentially triggered the release of IL-1RA, MCP-1 and IP-10 from the dendritic cells.. A different trend was observed with isoniazid and isoniazid-conditioned hepatocyte culture medium. Both stimulated dendritic cells to release comparable levels of cytokines (figure 5).  This data suggest that although factors released by hepatocytes upon drug exposure may be critical in controlling the phenotype and function of dendritic cells, and subsequent immune activation, soluble drugs, in particular isoniazid, are also capable of stimulating dendritic cells to release a variety of cytokines. In this respect, exosomes are currently being investigated to determine whether they transfer drug or other hepatocyte related factors to the immune system.

In the study by Oda et al, the authors used an integrated score of IL-1β, IL-8, and S100A9 mRNA levels as indicators for DILI risk assessment. While the authors were successful in grouping 96 test drugs into DILI-positive and DILI-negative, the integrated score system failed to identify pemoline (withdrawn from clinical use) and isoniazid (black box warning) as DILI-positive. The reason for this limitation was not discussed but data from our study shows that although isoniazid was relatively non-toxic to primary human hepatocytes, cell culture supernatants from hepatocytes cultured with isoniazid resulted in a distinct cytokine profile (IFN-γ, IL-12p40, IL-12p70, IL-17A and IL-10), suggesting that these cytokines may be directly involved in the pathogenesis of isoniazid-induced DILI. Hence, integrating multiple signals derived from in-vitro models could provide more reliable data to identify candidate drugs with potential immune-mediated DILI risk during drug development. Figure 6 is a scheme summarizing the findings of our study with each compound and how the different secreted mediators might regulate the immune response and the direct killing of drug-stressed hepatocytes.

Remarkably, of the twenty-one dendritic cell surface markers analysed, only CD40 expression was upregulated in response to one of the test compounds SMX-NO (and SMX-NO hepatocyte conditioned medium). This phenomenon has been previously documented by Sanderson et al. (Sanderson et al., 2007). Several co-stimulatory molecules were down regulated by SMX-NO and flucloxacillin treatment, namely CD54, CD58 and CD70, which might be expected to affect the activation state of the DC. Whereas, down regulation of CCR9 and CXCR4 may affect T cell recruitment and homing.

In conclusion, our study shows that hepatocytes release cytokines following exposure to hepatotoxic drugs and that these signals lead to the release of a discrete profile of dendritic cell cytokines. Future work will involve the use of a larger set of training compounds fit for the development of mechanism based methods. Furthermore, it will be important to develop advanced co-culture systems containing other cell types such as Kupffer cells and endothelial cells to define the key signalling pathways between liver and the immune system. A major limitation of our study and all in vitro assays being designed for the future prediction of DILI by caused by new drug candidates is the difficultly in translating the effects observed in model systems to what is observed in DILI patients. Thus, it is important to establish animal models of type B DILI with the same clinical phenotype as that reported in human patients. In this respect, Uetrecht and co-workers have established a promising model; the combination of CTLA-4 and PD1 inhibition seems to unmask liver injury induced by drugs such as isoniazid and amodiaquine (Mak et al., 2015b; Metushi et al., 2015). Depletion of CD8+ T-cells prior to drug exposure protects mice from liver injury (Mak et al., 2015), indicating that the adaptive immune system participates in the tissue injury. After further development it might be possible to explore how modulation of the innate immune system by drugs impacts on liver injury using this model.
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Figure legends
Figure 1. Drug- and concentration-dependent release of LDH and ATP depletion. (A) Primary human hepatocytes (105 cells) were incubated with graded concentrations of SMX-NO, flucloxacillin, amoxicillin or isoniazid for 24 hours at 37 °C and 5% CO2. LDH release and ATP depletion were measured using plate-based colorimetric and luminescence assays. (B) Similar experiments were conducted with primary human hepatocytes to compare the toxicity of flucloxacillin and piperacillin. Cells were plated at 105  cells/well and then incubated with flucloxacillin or piperacillin (0.5-10 mM) for 24 h, and cytotoxicity was determined by ATP depletion and LDH release assays (n = 3). 

Figure 2. Drug-induced HMGB1 release from primary human hepatocytes: Primary human hepatocytes were cultured with test drugs (A, SMX-NO; B, flucloxacillin; C, amoxicillin; D, isoniazid) for 24 h at 37 °C and 5% CO2. HMGB1 release from primary human hepatocytes into cell culture medium was analysed using ELISA and immunoblotting 

Figure 3. Disulphide HMGB1 stimulates dendritic cells to secrete cytokines and attenuates the threshold for T cell activation. Monocyte-derived dendritic cells from 2 separate donors (105) were cultured with four different isoforms of HMGB1, A-D (100 ng/ml) for 24 h, at 37 °C and 5% CO2. Dendritic cells treated with LPS (10 µg/ml) was used as positive control. (A) The levels of IFN-γ, IL-12p70, IL-12p40, IL-10, TNF-α and IL-6 were analysed using the ELISpot cytokine assay. Spot forming unit values in ELISpot images represent cytokine secreting cells. Spot forming unit values of 50 or more above the medium control were considered positive.  (B) Schematic representation of the various HMGB1 isoforms showing post-translational modifications of cysteine residues, A-D. (C) Naive T cells were cultured with mature autologous dendritic cells (25:1) in the presence SMX-NO (50 µM) ± disulphide HMGB1 for 7 days. Cultures were then plated out at 105 cells/well and restimulated with a fresh batch of autologous dendritic cells (4 x 103) in a U-bottomed flask. Plates were incubated for 48 h, 0.5 µCi of 3H-thymidine was added during the final 16 h of incubation to determine T cell proliferation. Data shows the mean and standard deviation of duplicate wells. (D) Cells were cultured as stated in (C) above and naive T cell priming determined using interferon-gamma ELISpot assay.


Figure 4. Dendritic cells released two distinct cytokine profiles when cultured with hepatocyte-conditioned medium. Primary human hepatocytes (5x105) were exposed to 3 different concentrations of test drugs or hepatocyte culture medium (negative control) for 24 h, at 37 °C and 5% CO2. Supernatants were collected and incubated with monocyte-derived dendritic cells (5x105) for a further 24h. Supernatants from dendritic cells were collected and analysed using LUMINEX. (A) Pro-inflammatory profile consisting of TNF-α, IL-6, IL-1α, IP-10 and IL-1β. (B) An isoniazid-specific profile (IFN-γ, IL-12p40, IL-12p70, IL-17A, and IL-10).
 
Figure 5. Cytokine secretion by dendritic cells exposed to hepatocyte condition medium or test drugs. Dendritic cells (5x105) were incubated with either supernatants from drug-treated hepatocytes (open bars) or test drugs (filled bars) for 24 h, at 37 °C and 5% CO2. (A) SMX-NO treatment. (B) Flucloxacillin treatment. (C) Isoniazid treatment. Cytokine secretions were determined using LUMINEX.

Figure 6: Summary of molecules released from primary human hepatocytes exposed to test drugs and the impact of secreted molecules on hepatocytes and the immune system. 
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